Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line …

A Sowunmi, G Ntadom, K Akano, FO Ibironke… - Infectious Diseases of …, 2019 - Springer
Background The development and spread of artemisinin-resistant Plasmodium falciparum
malaria in Greater Mekong Subregion has created impetus for continuing global monitoring …

Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast

S Borrmann, P Sasi, L Mwai, M Bashraheil, A Abdallah… - PloS one, 2011 - journals.plos.org
Background The emergence of artemisinin-resistant P. falciparum malaria in South-East
Asia highlights the need for continued global surveillance of the efficacy of artemisinin …

Recrudescent Plasmodium falciparum infections in children in an endemic area following artemisinin–based combination treatments: Implications for disease control

GO Gbotosho, TM Okuboyejo, CT Happi… - Asian Pacific Journal of …, 2011 - Elsevier
Objective To evaluate the features and risk factors associated with recrudescent infections
that arose following artemisinin-based combination drug treatment of the primary infections …

Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian …

A Sowunmi, K Akano, G Ntadom, AI Ayede… - Infectious Diseases of …, 2017 - Springer
Background Artemisinin-based combination treatments (ACTs) are the first-line treatments of
uncomplicated Plasmodium falciparum malaria in many endemic areas but there are few …

Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite …

OS Michael, GO Gbotosho, OA Folarin, T Okuboyejo… - Malaria journal, 2010 - Springer
Background Combination treatments, preferably containing an artemisinin derivative, are
recommended to improve efficacy and prevent Plasmodium falciparum drug resistance …

Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria

MK Muhindo, A Kakuru, P Jagannathan, A Talisuna… - Malaria journal, 2014 - Springer
Background Artemisinin-based combination therapy (ACT) is widely recommended as first-
line therapy for uncomplicated Plasmodium falciparum malaria worldwide. Artemisinin …

The temporal dynamics of Plasmodium species infection after artemisinin-based combination therapy (ACT) among asymptomatic children in the Hohoe municipality …

F Ansah, K Nyame, R Laryea, R Owusu, D Amon… - Malaria Journal, 2023 - Springer
Background The routine surveillance of asymptomatic malaria using nucleic acid-based
amplification tests is essential in obtaining reliable data that would inform malaria policy …

Therapeutic efficacy of artesunate–amodiaquine and artemether–lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015–2017

B Abuaku, NO Duah-Quashie, L Quaye, SA Matrevi… - Malaria Journal, 2019 - Springer
Background Routine surveillance on the therapeutic efficacy of artemisinin-based
combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of …

[HTML][HTML] Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children ten years following …

JC Ebenebe, G Ntadom, J Ambe… - The American journal …, 2018 - ncbi.nlm.nih.gov
The efficacies of 3-day regimens of artemether–lumefantrine (AL), artesunate–amodiaquine
(AA), and dihydroartemisinin–piperaquine (DHP) were evaluated in 910 children< 5 years …

[HTML][HTML] Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as …

GO Gbotosho, A Sowunmi, CT Happi… - The American journal …, 2011 - ncbi.nlm.nih.gov
The therapeutic efficacies of 3-day regimens of artesunate-amodiaquine and artemether-
lumefantrine during 5 years of adoption as first-line treatments were evaluated in 811≤ 12 …